Interview on the Market Herald with Wayne., page-27

hi v
WP dropped a ‘clue’ fair while back; in effect, successful IP needs to be linked with successful commercialization. To date the failure of the latter has proven costly to most investors in this stock.

The Vaccine was ‘our’ first hope and then the CardioCel, neither have been company ‘makers’, the former a huge drain on funds with little return.

The present? ...... still the exact same hurdles, funding and partners to complement the current IP. It will be interesting to see how the market now views this company, with no major seller and the last funding package in place.

Major positive, imo, if in conjunction with share price appreciation, is the issuing of new shares at the 90% 5 day average. Direct contrast to its history of issuing new shares at ever lower prices.

All that aside it still niggles me that SB is exiting with significant losses. That they were only here for the ID is quite a valid point but why not continue the ‘ride’ to years end and get a return multiples of what they have got? With China’s huge population, growing middle class, there should be huge interest in Anteris current direction.